<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000666</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 001</org_study_id>
    <nct_id>NCT00000666</nct_id>
  </id_info>
  <brief_title>A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection</brief_title>
  <official_title>A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate pyrimethamine as a prophylactic agent against toxoplasmic encephalitis in&#xD;
      individuals who are coinfected with HIV and latent Toxoplasma gondii.&#xD;
&#xD;
      Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard&#xD;
      treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine.&#xD;
      Continuous treatment is necessary to prevent recurrence of the disease, but constant use of&#xD;
      pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be&#xD;
      effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates&#xD;
      pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91&#xD;
      amendment, clindamycin arm was discontinued).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard&#xD;
      treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine.&#xD;
      Continuous treatment is necessary to prevent recurrence of the disease, but constant use of&#xD;
      pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be&#xD;
      effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates&#xD;
      pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91&#xD;
      amendment, clindamycin arm was discontinued).&#xD;
&#xD;
      Patients are randomized to receive pyrimethamine or placebo three times a week. All patients&#xD;
      must be on aerosolized pentamidine, trimethoprim / sulfamethoxazole (T/S), or dapsone for&#xD;
      Pneumocystis carinii pneumonia prophylaxis. Patients will be evaluated bi-weekly for the&#xD;
      first month and every other month thereafter for at least 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 1992</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <enrollment>600</enrollment>
  <condition>Toxoplasmosis, Cerebral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prophylactic treatment for Pneumocystis carinii pneumonia with aerosolized&#xD;
             pentamidine, dapsone, or trimethoprim / sulfamethoxazole.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Most medications not specifically excluded.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antivirals.&#xD;
&#xD;
          -  Antiretrovirals.&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Must be HIV positive or have an AIDS-defining illness OR be at known risk for HIV&#xD;
             infection and have a CD4 cell count &lt; 200/mm3 and no other known immunosuppressive&#xD;
             disease.&#xD;
&#xD;
          -  Must have positive titer for Toxoplasma gondii.&#xD;
&#xD;
          -  Must be or become a patient of a CPCRA physician.&#xD;
&#xD;
          -  May participate in other clinical trials as long as there is no potential activity&#xD;
             against Toxoplasma gondii or cross-toxicity among study drugs.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  History of ocular, pulmonary, or central nervous system (CNS) toxicity.&#xD;
&#xD;
          -  CNS lesions.&#xD;
&#xD;
          -  Neurologic deficits except peripheral neuropathy.&#xD;
&#xD;
          -  Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea&#xD;
             and/or vomiting.&#xD;
&#xD;
          -  Sensitivity to pyrimethamine.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  On-going therapy with clindamycin, fansidar, methotrexate, trimetrexate, spiramycin,&#xD;
             azithromycin, clarithromycin, 566C80, and/or sulfa agents other than anti-PCP agents.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of ocular, pulmonary, or central nervous system (CNS) toxicity.&#xD;
&#xD;
          -  CNS lesions or history of CNS lesions.&#xD;
&#xD;
          -  Neurologic deficits except peripheral neuropathy.&#xD;
&#xD;
          -  Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea&#xD;
             and/or vomiting.&#xD;
&#xD;
          -  Sensitivity to pyrimethamine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobson M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Besch CL</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>802044507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hill Health Corp</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Hosp / Med Ctr of Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive AIDS Alliance of Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Research and Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972109951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobson MA, Besch CL, Child C, Hafner R, Muth K, Deyton L. Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):195-8. doi: 10.1007/BF01964462.</citation>
    <PMID>1676364</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. Lancet. 1992 Feb 8;339(8789):333-4. doi: 10.1016/0140-6736(92)91649-s.</citation>
    <PMID>1346413</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994 Feb;169(2):384-94. doi: 10.1093/infdis/169.2.384.</citation>
    <PMID>8106772</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <keyword>Toxoplasmosis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

